<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066013</url>
  </required_header>
  <id_info>
    <org_study_id>FHREB 2009-093</org_study_id>
    <nct_id>NCT01066013</nct_id>
  </id_info>
  <brief_title>Antimicrobial De-escalation Strategy in Medical Patients</brief_title>
  <official_title>Antimicrobial De-escalation Strategy in Medical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to assess the impact of an antibiotic de-escalation
      strategy on the clinical outcomes (clinical cure or improvement) of medical patients related
      to the usage of of broad-spectrum antimicrobial agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, case-control, pilot study involving medical patients with serious
      infections who are prescribed meropenem or piperacillin/tazobactam, at Surrey Memorial
      Hospital. Patients in the experimental arm (cases) will be required to provide an informed
      consent. A team consisting of an infectious diseases specialist, medical microbiologist and
      clinical pharmacists will prospectively assess antimicrobial therapy in the enrolled subjects
      in the prospective arm and make recommendations for antimicrobial de-escalation.

      The control group will consist of subjects drawn from historic data of patients on the same
      medical unit(s) who will be matched based on age, sex, use of broadspectrum antibiotics
      (meropenem or piperacillin/tazobactam) and infectious diseases diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who had therapy with meropenem or piperacillin/tazobactam de-escalated by the de-escalation team.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy (clinical improvement or complete resolution of infection)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriateness of broadspectrum antibiotic (meropenem or piperacillin/tazobactam) prior to de-escalation</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost and consumption (usage data) of antibiotics</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infections</condition>
  <arm_group>
    <arm_group_label>Prospective Antimicrobial de-escalation arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrospective control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antimicrobial de-escalation strategy</intervention_name>
    <description>The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.</description>
    <arm_group_label>Prospective Antimicrobial de-escalation arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 years and over

          -  Suspected or confirmed infection for which a Meropenem and/or Piperacillin/Tazobactam
             is prescribed. This will include any patient who is other concomitant antibiotic(s)
             such as Vancomycin

          -  Subject admitted to SMH medical unit(s)

          -  Pregnant patient (or patients wishing to become pregnant)

        Exclusion Criteria:

          -  Age less than 19 years

          -  Granulocytopenia (&lt; 1x109/L)

          -  Allergy or intolerance to meropenem or piperacillin-tazobactam.

          -  Febrile Neutropenia

          -  Cystic Fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anisha Lakhani</name_title>
    <organization>Fraser Health Authority</organization>
  </responsible_party>
  <keyword>Antimicrobial De escalation</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Piperacillin tazobactam</keyword>
  <keyword>Medical patients</keyword>
  <keyword>Appropriate use</keyword>
  <keyword>Cost savings</keyword>
  <keyword>Antimicrobial De-escalation strategy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

